Clinical Trials Now Enrolling


Gliofocus – Phase 3 Study of Niraparib for Glioblastoma

Learn More

Trial Eligibility

Status: Recruiting

Visit ClinicalTrials.gov or use NCT identifier NCT06388733 to view inclusion criteria and additional study details.

Trial Screening

BDTX-1535 FOR RECURRENT HIGH-GRADE GLIOMA

Learn More

Trial Eligibility

Status: Recruiting

Visit ClinicalTrials.gov or use NCT identifier NCT06072586 to view inclusion criteria and additional study details.

Trial Screening

ONC201 IN NEWLY DIAGNOSED H3 K27M-MUTANT DIFFUSE GLIOMA

Learn More

Trial Eligibility

Status: Recruiting

Visit ClinicalTrials.gov or use NCT identifier NCT05580562 to view inclusion criteria and additional study details.

Trial Screening

Temsirolimus in Recurrent High-Grade Glioma

Learn More

Trial Eligibility

Status: Recruiting

Visit ClinicalTrials.gov or use NCT identifier NCT05773326 to view inclusion criteria and additional study details.

Trial Screening

AZD1390 FOR GRADE 4 GLIOMA

Learn More

Trial Eligibility

Status: Recruiting

Visit ClinicalTrials.gov or use NCT identifier NCT05182905 to view inclusion criteria and additional study details.

Trial Screening

SONODYNAMIC THERAPY IN RECURRENT HIGH-GRADE GLIOMA

Learn More

Trial Eligibility

Status: Recruiting

Visit ClinicalTrials.gov or use NCT identifier NCT04559685 to view inclusion criteria and additional study details.

Trial Screening

NIRAPARIB FOR NEWLY DIAGNOSED GLIOBLASTOMA

Learn More

Trial Eligibility

Status: Recruiting

Visit ClinicalTrials.gov or use NCT identifier NCT05076513 to view inclusion criteria and additional study details.

Trial Screening

PAMIPARIB IN NEWLY DIAGNOSED AND RECURRENT GLIOBLASTOMA

Learn More

Trial Eligibility

Status: Recruiting

Visit ClinicalTrials.gov or use NCT identifier NCT04614909 to view inclusion criteria and additional study details.

Trial Screening

RADIATION THERAPY FOR NEWLY DIAGNOSED ANAPLASTIC GLIOMA

Learn More

Trial Eligibility

Status: Recruiting

Visit ClinicalTrials.gov or use NCT identifier NCT00887146 to view inclusion criteria and additional study details.

Trial Screening

RADIATION THERAPY VS. OBSERVATION FOR NEWLY DIAGNOSED MENINGIOMA

Learn More

Trial Eligibility

Status: Recruiting

Visit ClinicalTrials.gov or use NCT identifier NCT03180268 to view inclusion criteria and additional study details.

Trial Screening

DSC-MRI FOR RECURRENT GLIOBLASTOMA

Learn More

Trial Eligibility

Status: Recruiting

Visit ClinicalTrials.gov or use NCT identifier NCT03115333 to view inclusion criteria and additional study details.

Trial Eligibility

RADIATION THERAPY PLANNING WITH FLUCICLOVINE PET FOR NEWLY DIAGNOSED GLIOBLASTOMA

Learn More

Trial Eligibility

Status: Recruiting

Visit ClinicalTrials.gov or use NCT identifier NCT04840069 to view inclusion criteria and additional study details.

Trial Screening

RADIATION THERAPY FOR BRAIN METASTASES

Learn More

Trial Eligibility

Status: Recruiting

Visit ClinicalTrials.gov or use NCT identifier NCT05438212 to view inclusion criteria and additional study details.

Trial Screening

SMO/AKT/ NF2/CDK INHIBITORS FOR PROGRESSIVE MENINGIOMAS

Learn More

Trial Eligibility

Status: Recruiting

Visit ClinicalTrials.gov or use NCT identifier NCT02523014 to view inclusion criteria and additional study details.

Trial Screening

SAFUSIDENIB (AB-218) FOR IDH1 MUTANT GLIOMA

Learn More

Trial Eligibility

Status: Recruiting

Visit ClinicalTrials.gov or use NCT identifier NCT05303519 to view inclusion criteria and additional study details.

Trial Screening

INFIGRATINIB FOR RECURRENT HIGH-GRADE GLIOMA

Learn More

Trial Eligibility

Status: Active, not recruiting

Visit ClinicalTrials.gov or use NCT identifier NCT04424966 to view inclusion criteria and additional study details.

Physician Information

RIBOCICLIB FOR RECURRENT GLIOBLASTOMA


Trial Eligibility

Status: Active, not recruiting

Visit ClinicalTrials.gov or use NCT identifier NCT02933736  to view inclusion criteria and additional study details.


CA-4948 IN RELAPSED OR REFRACTORY PRIMARY CNS LYMPHOMA

Learn More

Trial Eligibility

Status: Recruiting

Visit ClinicalTrials.gov or use NCT identifier NCT03328078 to view inclusion criteria and additional study details.

Trial Screening

RIBOCICLIB FOR RECURRENT MENINGIOMA


Trial Eligibility

Status: Active, not recruiting

Visit ClinicalTrials.gov or use NCT identifier NCT02933736  to view inclusion criteria and additional study details.

 


RIBOCICLIB PLUS EVEROLIMUS FOR RECURRENT HIGH-GRADE GLIOMA

Learn More

Trial Eligibility

Status: Completed

Visit ClinicalTrials.gov or use NCT identifier NCT03834740  to view inclusion criteria and additional study details.